Drugs in Dev.
Musculoskeletal
Phase II
Sweden 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study demonstrated significant effect on changes in bone and cartilage degradation after six months of treatment with MIV-711.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2020
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Details : MIV-711 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 31, 2017
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Details : MIV-711 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2016
Lead Product(s) : MIV-711
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
